摘要
目的研究重组组织型纤溶酶原激活物(r-tPA)治疗早期脑梗死的临床应用。方法比较r-tPA治疗组和对照组脑梗死患者治疗有效率和神经功能改善程度。结果r-tPA治疗组治疗有效率80.00%,对照组有效率55.00%,2组比较差异有显著性(P<0.05);从治疗1 d后起,r-tPA治疗组患者美国国立卫生研究院卒中量表(NIHSS)评分均明显低于对照组(均为P<0.05)。结论在严格控制适应证的前提下,r-tPA治疗早期脑梗死患者有效而且安全;r-tPA治疗早期脑梗死患者可不依赖头颅MR I和脑动脉介入技术,能够在一般医院开展。
Objective To study the clinical application of recombinant tissue plasminogen activator （r- tPA） for treating super early stage of cerebral infarction （CI）. Methods The effective rate and neurologic function improvement were compared in treatment group and control group. Results The effective rates were 80.00% in the r-tPA treatment group and 55.00% in control group,with significant difference （ P 〈 0.05 ）. From 1 day after treatment,the NIHSS score in r-tPA-trcatment group was significantly lower than that of control group （P 〈 0.05 for each）. Conclusion r-tPA is effective and safe in treating super-early cerebral infarction in case of strict control of which can be performed in the general hospital therefore it without cerebral MRI and intervention technique.
出处
《中国综合临床》
北大核心
2006年第10期873-875,共3页
Clinical Medicine of China
关键词
脑梗死
重组组织型纤溶酶原激活物
静脉溶栓
Cerebral infarction
Recombinant tissue plasminogen activator
Intravenous thrombolysis
